Sponsors / IOVA
IOVA

Iovance Biotherapeutics, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
8Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaNCT02360579IOVAPhase 2Completed2024-10-24Actual
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckNCT03083873IOVAPhase 2Completed2022-08-08Actual
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaNCT03108495IOVAPhase 2Terminated2025-08-22Actual
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928IOVAPhase 2Terminated2026-02-20Actual
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerNCT04614103IOVAPhase 2Recruiting2030-12Estimated
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.NCT05727904IOVAPhase 3Recruiting2028-03-01Estimated
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.NCT06481592IOVAPhase 2Recruiting2028-05Estimated
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaNCT07288203IOVAPhase 2Active not recruiting2032-12Estimated

Latest recorded trial changes

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

NCT03108495 · Iovance Biotherapeutics, Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Cohort 1 and 2: Objective Response Rate Description: To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Time frame: Up to 60 months Measure: Cohort 3: Adverse Events Description: To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events. Time frame: Up to 60 months Measure: Cohort 4: Adverse Events Description: To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events. Time frame: Up to 60 months Measure: Cohort 4: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR). Time frame: Up to 60 months Measure: Cohort 5: Adverse Events Description: To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events. Time frame: Up to 60 months Measure: Cohort 5: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR). Time frame: Up to 60 months

+ After

Measure: Cohort 1 and 2: Objective Response Rate Description: To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Time frame: Up to 60 months Measure: Cohort 3: Number of Participants With Adverse Events Description: To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events. Time frame: Up to 60 months Measure: Cohort 4: Number of Participants With Adverse Events Description: To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events. Time frame: Up to 60 months Measure: Cohort 4: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Time frame: Up to 60 months Measure: Cohort 5: Number of Participants With Adverse Events Description: To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events. Time frame: Up to 60 months Measure: Cohort 5: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Time frame: Up to 60 months

Check registry source
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

NCT03108495 · Iovance Biotherapeutics, Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Cohort 1 and 2: Objective Response Rate Measure: Cohort 3: Adverse Events Measure: Cohort 4: Efficacy and Adverse Events Measure: Cohort 5: Efficacy and Adverse Events

+ After

Measure: Cohort 1 and 2: Objective Response Rate Measure: Cohort 3: Adverse Events Measure: Cohort 4: Adverse Events Measure: Cohort 4: Efficacy/Objective Response Rate Measure: Cohort 5: Adverse Events Measure: Cohort 5: Efficacy/Objective Response Rate

Check registry source
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928 · Iovance Biotherapeutics, Inc.

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: To evaluate the feasibility of producing lifileucel using tumor samples obtained before (Cohort 3D) or during (Cohort 3E) frontline platinum doublet chemotherapy and pembrolizumab in patients with Stage IV NSCLC

+ After

Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: Percentage of patients for whom lifileucel is successfully manufactured and meets release specification

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

245 participants (planned)

+ After

225 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

9 Aug 2029

+ After

20 Feb 2026

Recruitment status changed

− Before

Recruiting

+ After

Terminated

Check registry source